

Assessing inflammatory status in cardiovascular disease: which markers to choose, what to measure? (ht88211)

Dimitris Tousoulis, Charalambos Antoniades, Christodoulos Stefanadis

Web only references

1. Willerson JT, Ridker PM. Inflammation as a Cardiovascular Risk Factor. *Circulation* 2004;**109**:II-2–10.
2. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. *Atherosclerosis* 2003;**170**:191–203.
3. Moreno PR, Falk E, Palacios IF, *et al.* Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. *Circulation* 1994;**90**:775–8.
4. Lefkowitz RJ, Willerson JT. Prospects for cardiovascular research. *JAMA* 2001;**285**:581–7.
5. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. *Circulation* 2001;**103**:1718–20.
6. Alonso J, Sanchez de Miguel L, Monton M, *et al.* Endothelial cytosolic proteins bind to the 3' untranslated region of endothelial nitric oxide synthase mRNA: regulation by tumor necrosis factor alpha. *Mol Cell Biol* 1997;**17**:5719–26.
7. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation* 2000;**102**:2165–8.
8. Yeh ET, Anderson HV, Pasceri V, *et al.* C-reactive protein: linking inflammation to cardiovascular complications. *Circulation* 2001;**104**:974–5.
9. Cesari M, Penninx BW, Newman AB, *et al.* Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. *Circulation* 2003;**108**:2317–22.
10. Harris TB, Ferrucci L, Tracy RP, *et al.* Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. *Am J Med* 1999;**106**:506–12.
11. Jenny NS, Tracy RP, Ogg MS, *et al.* In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease. *Arterioscler Thromb Vasc Biol* 2002;**22**:2066–71.
12. Cesari M, Penninx BW, Newman AB, *et al.* Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). *Am J Cardiol* 2003;**92**:522–8.
13. Ridker PM, Rifai N, Stampfer MJ, *et al.* Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. *Circulation* 2000;**101**:1767–72.
14. Ridker PM, Rifai N, Pfeffer M, *et al.* Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. *Circulation* 2000;**101**:2149–53.
15. Diez-Ruiz A, Tilz GP, Zangerle R, *et al.* Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. *Eur J Haematol* 1995;**54**:1–8.
16. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. *Cytokine Growth Factor Rev* 1996;**7**:231–40.

17. Pradhan AD, Manson JE, Rossouw JE, *et al.* Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. *JAMA* 2002;**288**:980–7.
18. Pai JK, Pischon T, Ma J, *et al.* Inflammatory markers and the risk of coronary heart disease in men and women. *N Engl J Med* 2004;**351**:2599–610.
19. Heeschen C, Dimmeler S, Hamm CW, *et al.* Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. *Circulation* 2003;**107**:2109–14.
20. Heeschen C, Dimmeler S, Hamm CW, *et al.* Pregnancy-associated plasma protein-A levels in patients with acute coronary syndromes: comparison with markers of systemic inflammation, platelet activation, and myocardial necrosis. *J Am Coll Cardiol* 2005;**45**:229–37.
21. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. *J Intern Med* 2002;**252**:283–94.
22. Harb TS, Zareba W, Moss AJ, *et al.* Association of C-reactive protein and serum amyloid A with recurrent coronary events in stable patients after healing of acute myocardial infarction. *Am J Cardiol* 2002;**89**:216–21.
23. Liuzzo G, Biasucci LM, Gallimore JR, *et al.* The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. *N Engl J Med* 1994;**331**:417–24.
24. Morrow DA, Rifai N, Antman EM, *et al.* C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. *J Am Coll Cardiol* 1998;**31**:1460–5.
25. Heeschen C, Hamm CW, Bruemmer J, *et al.* Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. *Journal of the American College of Cardiology* 2000;**35**:1535.
26. Lindahl B, Toss H, Siegbahn A, *et al.* Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. *The New England Journal Of Medicine* 2000;**343**:1139.
27. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. *Clin Chem* 1999;**45**:2136–41.
28. Khuseyinova N, Imhof A, Trischler G, *et al.* Determination of C-reactive protein: comparison of three high-sensitivity immunoassays. *Clin Chem* 2003;**49**:1691–5.
29. Koenig W, Sund M, Frohlich M, *et al.* Refinement of the association of serum C-reactive protein concentration and coronary heart disease risk by correction for within-subject variation over time: the MONICA Augsburg studies, 1984 and 1987. *Am J Epidemiol* 2003;**158**:357–64.
30. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. *Thromb Haemost* 2003;**89**:601–9.
31. Whitehead AS, de Beer MC, Steel DM, *et al.* Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. *J Biol Chem* 1992;**267**:3862–3867.

32. Chait A, Han CY, Oram JF, *et al.* Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? *J Lipid Res* 2005;**46**:389–403.
33. Ridker PM. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. *Circulation* 1998;**98**:839.
34. Jousilahti P, Salomaa V, Rasi V, *et al.* The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease--baseline findings of the PAIS project. *Atherosclerosis* 2001;**156**:451–6.
35. Leinonen E, Hurt-Camejo E, Wiklund O, *et al.* Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. *Atherosclerosis* 2003;**166**:387.
36. Leinonen ES, Hiukka A, Hurt-Camejo E, *et al.* Low-grade inflammation, endothelial activation and carotid intima-media thickness in type 2 diabetes. *Journal of Internal Medicine* 2004;**256**:119–127.
37. Ridker PM, Hennekens CH, Roitman-Johnson B, *et al.* Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. *Lancet* 1998;**351**:88–92.
38. Hwang SJ, Ballantyne CM, Sharrett AR, *et al.* Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. *Circulation* 1997;**96**:4219–25.
39. de Lemos JA, Hennekens CH, Ridker PM. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. *J Am Coll Cardiol* 2000;**36**:423–6.
40. Ridker PM, Hennekens CH, Rifai N, *et al.* Hormone replacement therapy and increased plasma concentration of C-reactive protein. *Circulation* 1999;**100**:713–6.
41. Blankenberg S, Rupprecht HJ, Bickel C, *et al.* Circulating cell adhesion molecules and death in patients with coronary artery disease. *Circulation* 2001;**104**:1336–42.
42. Haim M, Tanne D, Boyko V, *et al.* Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the Bezafibrate Infarction Prevention (BIP) Study. *J Am Coll Cardiol* 2002;**39**:1133–8.
43. Tanne D, Haim M, Boyko V, *et al.* Soluble intercellular adhesion molecule-1 and risk of future ischemic stroke: a nested case-control study from the Bezafibrate Infarction Prevention (BIP) study cohort. *Stroke* 2002;**33**:2182–6.
44. Stehouwer CD, Gall MA, Twisk JW, *et al.* Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. *Diabetes* 2002;**51**:1157–65.
45. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. *Atheroscler Suppl* 2005;**6**:21–9.
46. Urbich C, Dimmeler S. CD40 and vascular inflammation. *Can J Cardiol* 2004;**20**:681–3.
47. Heeschen C, Dimmeler S, Hamm CW, *et al.* Soluble CD40 ligand in acute coronary syndromes. *N Engl J Med* 2003;**348**:1104–11.

48. Ahn ER, Lander G, Jy W, *et al.* Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. *Thromb Res* 2004;**114**:143–8.
49. Cipollone F, Ferri C, Desideri G, *et al.* Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. *Circulation* 2003;**108**:2776–82.
50. Caslake MJ, Packard CJ, Suckling KE, *et al.* Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. *Atherosclerosis* 2000;**150**:413.
51. Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. *Current Opinion in Pharmacology* 2001;**1**:121.
52. Yang EH, McConnell JP, Lennon RJ, *et al.* Lipoprotein-Associated Phospholipase A2 Is an Independent Marker for Coronary Endothelial Dysfunction in Humans. *Arterioscler Thromb Vasc Biol* 2006;**26**:106–111.
53. Zhang R, Brennan M-L, Fu X, *et al.* Association Between Myeloperoxidase Levels and Risk of Coronary Artery Disease. *JAMA* 2001;**286**:2136–2142.